Rhumbline Advisers lifted its stake in Emergent Biosolutions, Inc. (NYSE:EBS) by 2.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 70,829 shares of the biopharmaceutical company’s stock after purchasing an additional 1,825 shares during the quarter. Rhumbline Advisers owned about 0.17% of Emergent Biosolutions worth $2,865,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of EBS. Riverhead Capital Management LLC increased its holdings in shares of Emergent Biosolutions by 102.8% in the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,542 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Emergent Biosolutions by 23.2% in the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 587 shares during the last quarter. First Quadrant L P CA acquired a new stake in shares of Emergent Biosolutions in the third quarter valued at approximately $157,000. Meeder Asset Management Inc. increased its holdings in shares of Emergent Biosolutions by 94.7% in the third quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 2,302 shares during the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in shares of Emergent Biosolutions in the third quarter valued at approximately $191,000. 92.70% of the stock is owned by hedge funds and other institutional investors.

Emergent Biosolutions, Inc. (NYSE:EBS) traded up $1.13 during mid-day trading on Friday, reaching $43.55. The company’s stock had a trading volume of 576,204 shares, compared to its average volume of 537,145. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37. The firm has a market capitalization of $1,802.75, a PE ratio of 23.04, a price-to-earnings-growth ratio of 1.20 and a beta of 1.24. Emergent Biosolutions, Inc. has a one year low of $27.94 and a one year high of $44.97.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.32. The company had revenue of $149.43 million during the quarter, compared to analysts’ expectations of $124.55 million. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.56 earnings per share. analysts predict that Emergent Biosolutions, Inc. will post 1.64 EPS for the current fiscal year.

EBS has been the subject of several recent research reports. BidaskClub raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. Zacks Investment Research raised Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Wednesday, October 25th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Emergent Biosolutions has a consensus rating of “Buy” and an average price target of $46.00.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 47,983 shares of the firm’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $41.88, for a total transaction of $2,009,528.04. Following the completion of the sale, the chairman now owns 1,550,216 shares of the company’s stock, valued at $64,923,046.08. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Adam Havey sold 7,885 shares of the firm’s stock in a transaction on Wednesday, September 27th. The stock was sold at an average price of $39.50, for a total value of $311,457.50. Following the sale, the executive vice president now directly owns 33,931 shares of the company’s stock, valued at approximately $1,340,274.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 255,308 shares of company stock valued at $10,379,634. 16.50% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/rhumbline-advisers-buys-1825-shares-of-emergent-biosolutions-inc-ebs/1756003.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.